Replies to post #146252 on Innovation Pharmaceuticals Inc (IPIX)

[CallMeCrazy]

Yes, Kevetrin, in my estimation, will generate 10s of billions of dollars in revenue, most of which will come from being a part of numerous combination therapies.

Ovarian cancer is the indication that will get K FDA approval, but I believe lung cancer is the indication that will bring K blockbuster status. Consider that:

"The p53 gene is damaged, missing or under-expressed in 42 percent of common cancers and 70 percent of lung cancers."

Further consider that:

It's [p53] by far the most common mutation in cancer. Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute.

http://www.news-medical.net/news/20151121/Crucial-tumor-suppressing-gene-protects-immune-attack-against-lung-cancer.aspx

Adding to the difficulties in treating lung cancer:

The majority of lung cancer patients are diagnosed with advanced disease (stage IIIb/IV). For these patients, conventional treatment options including surgery, chemotherapy, and radiation are unlikely to result in cure, although they may significantly improve survival and provide symptom relief.

http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lung-cancer

This suggest that most lung cancer patients, when diagnosed, require advanced-combination treatments of drugs and immunotherapies like Opdivo or Keytruda, whose effectiveness is only about 20%. I believe adding Kevetrin to these "combos" will greatly improve the effectiveness of these two immunotherapies and other lung cancer drugs, and will make this indication CTIX's most lucrative.